Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Asian head and neck cancer patients live longer with the immunotherapy pembrolizumab than the overall population, according to a sub-analysis of the KEYNOTE-012 trial presented at the ESMO Asia 2016 Congress in Singapore
The study in over 5,500 women found that younger patients and those who had taken hormone replacement therapy (HRT) were less likely to adhere to their medicine.
Pain relief and other forms of supportive care for cancer patients are insufficient, researchers will report at the ESMO Asia 2016 Congress
Research to be presented at the ESMO Asia 2016 Congress
The ESMO Asia 2016 Congress announces its press programme today. The meeting brings together cancer experts in Singapore, from 16 to 19 December 2016
Late registration for ESMO Asia 2016 Congress ends 9 November
The 4th edition of the ESMO Symposium on Immuno-Oncology begins Friday 4 November 2016 in Lausanne, Switzerland
ESMO 2016 Congress has broken records, not only of attendance, but in terms of the quality science being presented, that will impact the practice of oncology
A phase III trial of sunitinib has met its primary endpoint of disease-free survival for adjuvant treatment of high-risk renal cell carcinoma after nephrectomy, researchers report at the ESMO 2016 Congress in Copenhagen.
Neoadjuvant chemotherapy with an anthracycline plus ifosfamide was associated with significant survival gains in patients with soft tissue sarcoma of the trunk or extremities who are at high-risk of recurrence, in an interim analysis that led to the early discontinuation of a trial presented today at the ESMO 2016 Congress in Copenhagen.
A phase III randomized controlled trial of custirsen in combination with cabazitaxel/prednisone in patients with previously-treated metastatic, castration-resistant prostate cancer has shown no significant survival gains compared to cabazitaxel/prednisone alone, according to data presented at the ESMO 2016 Congress in Copenhagen.
MEK inhibitor selumetinib in combination with docetaxel does not improve progression free or overall survival in individuals with KRAS-mutant non-small-cell lung cancer (NSCLC), according to data presented at the ESMO 2016 Congress in Copenhagen.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
